MSH Capital Advisors LLC Boosts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

MSH Capital Advisors LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 11.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,371 shares of the medical research company’s stock after purchasing an additional 246 shares during the quarter. MSH Capital Advisors LLC’s holdings in IQVIA were worth $418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of IQV. Brighton Jones LLC raised its position in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares during the last quarter. Canada Post Corp Registered Pension Plan bought a new stake in IQVIA in the 4th quarter worth approximately $572,000. Guggenheim Capital LLC grew its position in IQVIA by 5.3% in the 4th quarter. Guggenheim Capital LLC now owns 22,552 shares of the medical research company’s stock worth $4,432,000 after purchasing an additional 1,140 shares during the period. NFJ Investment Group LLC grew its position in IQVIA by 20.5% in the 4th quarter. NFJ Investment Group LLC now owns 36,893 shares of the medical research company’s stock worth $7,250,000 after purchasing an additional 6,282 shares during the period. Finally, Marshall Wace LLP grew its position in IQVIA by 85.4% in the 4th quarter. Marshall Wace LLP now owns 954,294 shares of the medical research company’s stock worth $187,528,000 after purchasing an additional 439,649 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Trading Up 2.2%

Shares of IQV opened at $190.08 on Thursday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a 50 day simple moving average of $168.77 and a two-hundred day simple moving average of $169.04. The firm has a market cap of $32.31 billion, a P/E ratio of 27.51, a price-to-earnings-growth ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $2.64 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on IQV. Redburn Partners set a $188.00 target price on shares of IQVIA in a research report on Friday, May 23rd. Robert W. Baird increased their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Barclays increased their price objective on shares of IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 23rd. Finally, Evercore ISI increased their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 9th. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $228.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.